Erudio Healtherudio.com
Sponsor
Sichuan Baili Pharmaceutical trials: what clinicians said in public
HCP commentary reports on 3 clinical trials sponsored by Sichuan Baili Pharmaceutical: PANKU-Breast02, PANKU-Lung01 and PANKU-Lung03. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Sichuan Baili Pharmaceutical Co., Ltd.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| PANKU-Lung03 NCT06500026 · Sichuan Baili Pharmaceutical Co., Ltd. | recurrent small cell lung cancer | Phase 3 | 34 | 5 | Focused | Nov 19, 2026 | Preview |
| PANKU-Breast02 NCT06382142 · Sichuan Baili Pharmaceutical Co., Ltd. | unresectable locally advanced or metastatic triple-negative breast cancer | Phase 3 | 118 | 31 | Focused | Nov 15, 2026 | Preview |
| PANKU-Lung01 NCT06382116 · Sichuan Baili Pharmaceutical Co., Ltd. | advanced non-small cell lung cancer after EGFR-TKI failure | Phase 3 | 97 | 37 | Focused | Nov 4, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NCT06437509 NCT06437509 · Sichuan Baili Pharmaceutical Co., Ltd. FocusedView → | extensive-stage small-cell lung cancer | Phase 2 | Focused | View | |||
| NCT05194982 NCT05194982 · Sichuan Baili Pharmaceutical Co., Ltd. FocusedView → | Not given | Phase 1 | Focused | View | |||